Stephen Davis Acadia Pharmaceuticals Inc (ACAD) insider trading activity

Stephen Davis is CEO of ACADIA PHARMACEUTICALS INC. Currently has a direct ownership of 186,555 shares of ACAD, which is worth approximately $3.04 Million. The most recent transaction as insider was on Aug 19, 2024, when has been sold 31,747 shares (Common Stock) at a price of $15.28 per share, resulting in proceeds of $485,094. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 187K

0% 3M change

109.3% 12M change

Total Value Held $3.04 Million

STEPHEN DAVIS Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 19 2024	SELL Open market or private sale	$485,094 $15.28 p/Share	31,747 Reduced 14.54%	186,555 Common Stock
Aug 16 2024	BUY Grant, award, or other acquisition	-	62,115 Added 22.15%	218,302 Common Stock
May 02 2024	SELL Open market or private sale	$193,573 $16.94 p/Share	11,427 Reduced 6.86%	155,231 Common Stock
May 01 2024	BUY Exercise of conversion of derivative security	-	22,391 Added 11.84%	166,658 Common Stock
Apr 08 2024	SELL Open market or private sale	$474,877 $17.87 p/Share	26,574 Reduced 15.55%	144,267 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	-	51,999 Added 23.33%	170,841 Common Stock
Mar 27 2024	SELL Open market or private sale	$317,080 $17.9 p/Share	17,714 Reduced 12.97%	118,842 Common Stock
Mar 25 2024	BUY Grant, award, or other acquisition	-	34,666 Added 20.25%	136,556 Common Stock
Feb 26 2024	SELL Open market or private sale	$137,584 $24.67 p/Share	5,577 Reduced 5.19%	101,890 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	10,946 Added 9.24%	107,467 Common Stock
Jan 08 2024	SELL Open market or private sale	$111,810 $29.96 p/Share	3,732 Reduced 3.72%	96,521 Common Stock
Jan 06 2024	BUY Exercise of conversion of derivative security	-	9,528 Added 8.68%	100,253 Common Stock
Oct 06 2023	SELL Open market or private sale	$1,132,323 $21.96 p/Share	51,563 Reduced 36.65%	89,131 Common Stock
Oct 05 2023	BUY Exercise of conversion of derivative security	-	103,999 Added 42.5%	140,694 Common Stock
Jul 14 2023	SELL Open market or private sale	$3,004,000 $30.04 p/Share	100,000 Reduced 73.16%	36,695 Common Stock
Jul 14 2023	BUY Exercise of conversion of derivative security	$2,077,000 $20.77 p/Share	100,000 Added 42.25%	136,695 Common Stock
Jul 12 2023	SELL Open market or private sale	$1,380,355 $25.05 p/Share	55,104 Reduced 60.03%	36,695 Common Stock
Jul 11 2023	SELL Open market or private sale	$412,450 $25.0 p/Share	16,498 Reduced 15.23%	91,799 Common Stock
May 01 2023	SELL Open market or private sale	$165,331 $21.18 p/Share	7,806 Reduced 6.72%	108,297 Common Stock
Apr 29 2023	BUY Exercise of conversion of derivative security	-	15,625 Added 11.86%	116,103 Common Stock
Apr 06 2023	SELL Open market or private sale	$155,849 $18.16 p/Share	8,582 Reduced 7.87%	100,478 Common Stock
Apr 05 2023	BUY Exercise of conversion of derivative security	-	17,333 Added 13.71%	109,060 Common Stock
Feb 24 2023	SELL Open market or private sale	$72,321 $18.78 p/Share	3,851 Reduced 4.03%	91,727 Common Stock
Feb 23 2023	BUY Exercise of conversion of derivative security	-	10,945 Added 10.27%	95,578 Common Stock
Jan 09 2023	SELL Open market or private sale	$66,875 $17.13 p/Share	3,904 Reduced 4.41%	84,633 Common Stock

Also insider at

HRTX

HERON THERAPEUTICS, INC. Healthcare

Director

BLCM

BELLICUM PHARMACEUTICALS, INC Healthcare

Director

Stephen Davis

CEO

Houston, TX

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACAD shares.

Notify only if

Value

Insider Trading

Get notified when an Acadia Pharmaceuticals Inc insider buys or sells ACAD shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACADIA PHARMACEUTICALS INC

Track Activities on ACAD

Account